Adherence to the 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline on the Use of Oral Anticoagulant Agents in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study

Ayman J Hammoudeh, Yousef Khader, Nazih Kadri, Eyas Al-Mousa, Yahya Badaineh, Laith Habahbeh, Ramzi Tabbalat, Hesham Janabi, Imad A Alhaddad, Ayman J Hammoudeh, Yousef Khader, Nazih Kadri, Eyas Al-Mousa, Yahya Badaineh, Laith Habahbeh, Ramzi Tabbalat, Hesham Janabi, Imad A Alhaddad

Abstract

Background: There is a scarcity of studies that evaluate adherence to the utilization of guideline-recommended oral anticoagulant agents (OACs) in patients with atrial fibrillation (AF) in the Middle East. The Jordan Atrial Fibrillation (JoFib) Study evaluated baseline clinical profiles and the utilization of OACs, including vitamin K antagonists (VKAs) and direct OACs (DOACs), in patients with valvular AF (VAF) and nonvalvular AF (NVAF) according to the 2019 focused update of the 2014 AHA/ACC/HRS guidelines.

Methods: Consecutive patients with AF were enrolled in 29 hospitals and outpatient clinics. The use of OACs was evaluated in patients with VAF and NVAF according to the prespecified guideline.

Results: Of 2000 patients, 177 (8.9%) had VAF and 1823 (91.1%) had NVAF. A VKA was prescribed for 88.1% of the VAF group. In the NVAF group, 1468 (80.5%) of patients had a high CHA2DS2-VASc score, i.e., a score of ≥3 in women and ≥2 in men; 202 (11.1%) patients had an intermediate CHA2DS2-VASc score, i.e., a score of 2 in women and 1 in men; and 153 (8.4%) patients had a low CHA2DS2-VASc score, i.e., a score of 1 in women and 0 in men. Of patients with a high CHA2DS2-VASc score, 1204 (82.0%) received OACs, including DOACs for 784 (53.4%) and VKA for 420 (28.6%) patients. Among patients with an intermediate score, OACs were prescribed for 148 (73.3%) patients, including 107 (53.0%) who received DOACs and 41 (20.3%) patients who received VKA. In patients with a low score, OACs were omitted in 94 (61.4%) patients and prescribed for 59 (38.6%) patients. Multivariate analysis showed that age between 50 and 70 years, CHA2DS2-VASc score of ≥2, a diagnosis of stroke or systemic embolization, and nonparoxysmal AF were significantly associated with increased odds of OAC prescription.

Conclusions: The current status of the utilization of OACs in Middle Eastern AF patients appears to be promising and is consistent with the 2019 focused update of the 2014 AHA/ACC/HRS guideline. This trial is registered with NCT03917992.

Conflict of interest statement

The authors have no conflicts of interests.

Copyright © 2021 Ayman J. Hammoudeh et al.

Figures

Figure 1
Figure 1
Use of anticoagulant agents in patients with nonvalvular AF according to the CHA2DS2-VASc score. DOACs: direct oral anticoagulant agents; LMWH: low molecular weight heparin; VKA: vitamin K antagonist.

References

    1. Lippi G., Sanchis-Gomar F. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. International Journal of Stroke. 2020 doi: 10.1177/1747493020905964.
    1. Ribeiro A. L., Otto C. M. Heartbeat: the worldwide burden of atrial fibrillation. Heart. 2018;104(24):1987–1988. doi: 10.1136/heartjnl-2018-314443.
    1. López-López J. A., Sterne J. A. C., Thom H. H. Z., et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;359, article j5058 doi: 10.1136/bmj.j5058.
    1. Thomas K. L., Jackson L. R., 2nd, Shrader P., et al. Prevalence, characteristics, and outcomes of valvular heart disease in patients with atrial fibrillation: insights from the ORBIT-AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation) Journal of the American Heart Association. 2017;6(12, article e006475) doi: 10.1161/JAHA.117.006475.
    1. Pan K. L., Singer D. E., Ovbiagele B., Wu Y. L., Ahmed M. A., Lee M. Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis. Journal of the American Heart Association. 2017;6(7, article e005835) doi: 10.1161/JAHA.117.005835.
    1. January C. T., Wann L. S., Calkins H., et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology. 2019;74(1):104–132. doi: 10.1016/j.jacc.2019.01.011.
    1. Borre E. D., Goode A., Raitz G., et al. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thrombosis and Haemostasis. 2018;118(12):2171–2187. doi: 10.1055/s-0038-1675400.
    1. Boriani G., Proietti M., Laroche C., et al. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. Europace. 2018;20(5):747–757. doi: 10.1093/europace/eux301.
    1. Magnani J. W., Norby F. L., Agarwal S. K., et al. Racial differences in atrial fibrillation-related cardiovascular disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. JAMA Cardiology. 2016;1(4):433–441. doi: 10.1001/jamacardio.2016.1025.
    1. Chugh S. S., Havmoeller R., Narayanan K., et al. Worldwide epidemiology of atrial fibrillation:a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–847. doi: 10.1161/CIRCULATIONAHA.113.005119.
    1. Camm A. J., Fox K. A. A. Strengths and weaknesses of ‘real-world’ studies involving non-vitamin K antagonist oral anticoagulants. Open Heart. 2018;5(1, article e000788) doi: 10.1136/openhrt-2018-000788.
    1. Bassand J. P., Virdone S., Goldhaber S. Z., et al. Early risks of death, stroke/systemic embolism, and major bleeding in patients with newly diagnosed atrial fibrillation. Circulation. 2019;139(6):787–798. doi: 10.1161/CIRCULATIONAHA.118.035012.
    1. Azar R. R., Ragy H., Kozan O., et al. Antithrombotic treatment pattern in newly diagnosed atrial fibrillation patients and 2-year follow-up results for dabigatran-treated patients in the Africa/Middle Eastern region: phase II results from the GLORIA-AF Registry Program. Journal of the American College of Cardiology. 2020;75, article 2290(11_Supplement_1) doi: 10.1016/S0735-1097(20)32917-X.
    1. Morillo C. A., Banerjee A., Perel P., Wood D., Jouven X. Atrial fibrillation: the current epidemic. Journal of Geriatric Cardiology. 2017;14(3):195–203.
    1. Healey J. S., Oldgren J., Ezekowitz M., et al. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. Lancet. 2016;388(10050):1161–1169. doi: 10.1016/S0140-6736(16)30968-0.
    1. al-Shamkhani W., Ayetey H., Lip G. Y. H. Atrial fibrillation in the Middle East: unmapped, underdiagnosed, undertreated. Expert Review of Cardiovascular Therapy. 2018;16(5):341–348. doi: 10.1080/14779072.2018.1457953.
    1. Chugh S. S., Roth G. A., Gillum R. F., Mensah G. A. Global burden of atrial fibrillation in developed and developing nations. Global Heart. 2020;9(1):113–119. doi: 10.1016/j.gheart.2014.01.004.
    1. Allan V., Honarbakhsh S., Casas J. P., et al. Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population- based cohorts of 20 million participants. Thrombosis and Haemostasis. 2017;117(5):837–850. doi: 10.1160/th16-11-0825.
    1. Salam A. M. Atrial fibrillation in Middle Eastern Arabs and South Asians: summary of published articles in the Arabian Gulf. Heart Views. 2019;20(4):158–165. doi: 10.4103/HEARTVIEWS.HEARTVIEWS_116_19.
    1. Apostolakis S., Zubaid M., Rashed W. A., et al. Assessment of stroke risk in Middle Eastern patients with atrial fibrillation: the Gulf SAFE registry. International Journal of Cardiology. 2013;168(2):1644–1646. doi: 10.1016/j.ijcard.2013.02.003.
    1. Salam A. M., AlBinali H. A., al-Mulla A. W., Singh R., Suwaidi J. A. Secular trends, treatments, and outcomes of Middle Eastern Arab and South Asian patients hospitalized with atrial fibrillation. Angiology. 2013;64(7):498–504. doi: 10.1177/0003319712460332.
    1. AlAwwa I., al-Hindi R., Alfraihat N., et al. Prevalence and associated factors of undiagnosed atrial fibrillation among end-stage renal disease patients on maintenance haemodialysis: a cross-sectional study. BMC Cardiovascular Disorders. 2020;20(1):p. 186. doi: 10.1186/s12872-020-01473-6.
    1. el Kadri M., Bazargani N., Farghaly M., et al. Profiling clinical characteristics and treatment patterns among non-valvular atrial fibrillation patients: a real-world analysis in Dubai, United Arab Emirates. Open Medicine Journal. 2019;6(1):33–41. doi: 10.2174/1874220301906010033.
    1. Hajj M., Ajrouche R., Zein S., Rachidi S., Awada S., al-Hajje A. Evaluation of risk factors and drug adherence in the occurrence of stroke in patients with atrial fibrillation. Pharmacy Practice. 2020;18(2):p. 1860. doi: 10.18549/PharmPract.2020.2.1860.
    1. el-Deeb M. H., Sulaiman K. J., al Riyami A. A., et al. 2014 Oman Heart Association protocol for the management of acute atrial fibrillation. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine. 2014;13(3):117–127. doi: 10.1097/hpc.0000000000000015.
    1. Zubaid M., Saad H., Ridha M., et al. Quality of anticoagulation with warfarin across Kuwait. Hellenic Journal of Cardiology. 2013;54(2):102–106.
    1. Lip G. Y. H., Nieuwlaat R., Pisters R., Lane D. A., Crijns H. J. G. M. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263–272. doi: 10.1378/chest.09-1584.
    1. Pisters R., Lane D. A., Nieuwlaat R., de Vos C. B., Crijns H. J. G. M., Lip G. Y. H. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–1100. doi: 10.1378/chest.10-0134.
    1. Lip G. Y. H., Brechin C. M., Lane D. A. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest. 2012;142(6):1489–1498. doi: 10.1378/chest.11-2888.
    1. Zubaid M., Rasheed W. A., Alsheikh-Ali A. A., et al. Gulf Survey of Atrial Fibrillation Events (Gulf SAFE): design and baseline characteristics of patients with atrial fibrillation in the Arab Middle East. Circulation. Cardiovascular Quality and Outcomes. 2011;287:162–173.
    1. Li Y. G., Miyazawa K., Wolff A., et al. One-year risks of stroke and mortality in patients with atrial fibrillation from different clinical settings: the Gulf SAFE registry and Darlington AF registry. International Journal of Cardiology. 2019;274:158–162. doi: 10.1016/j.ijcard.2018.08.091.
    1. Borschel C. S., Schnabel R. B. The imminent epidemic of atrial fibrillation and its concomitant diseases - myocardial infarction and heart failure - a cause for concern. International Journal of Cardiology. 2019;287:162–173. doi: 10.1016/j.ijcard.2018.11.123.
    1. Camm A. J., Amarenco P., Haas S., et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. European Heart Journal. 2016;37(14):1145–1153. doi: 10.1093/eurheartj/ehv466.
    1. Alsheikh-Ali A. A., Omar M. I., Raal F. J., et al. Cardiovascular risk factor burden in Africa and the Middle East: the Africa Middle East Cardiovascular Epidemiological (ACE) study. PLoS One. 2014;9(8, article e102830) doi: 10.1371/journal.pone.0102830.
    1. Boriani G., Proietti M., Laroche C., et al. Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. EP Europace. 2019;21(7):1013–1022. doi: 10.1093/europace/euz032.
    1. Xue Z., Zhang H. Non-vitamin k antagonist oral anticoagulants versus warfarin in Asians with atrial fibrillation: meta-analysis of randomized trials and real-world studies. Stroke. 2019;50(10):2819–2828. doi: 10.1161/STROKEAHA.119.026054.
    1. Bose A., O'Neal W. T., Wu C., et al. Sex differences in risk factors for incident atrial fibrillation (from the Reasons for Geographic and Racial Differences in Stroke [REGARDS] Study) The American Journal of Cardiology. 2019;123(9):1453–1457. doi: 10.1016/j.amjcard.2019.01.056.
    1. Nabauer M., Gerth A., Limbourg T., et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. EP Europace. 2009;11(4):423–434. doi: 10.1093/europace/eun369.
    1. Friberg J., Scharling H., Gadsboll N., Truelsen T., Jensen G. B. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study) The American Journal of Cardiology. 2004;94(7):889–894. doi: 10.1016/j.amjcard.2004.06.023.
    1. Eikelboom J. W., O'Donnell M., Yusuf S., et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. American Heart Journal. 2010;159(3):348–353.e1. doi: 10.1016/j.ahj.2009.08.026.
    1. Letsas K., Karamichalakis N., Vlachos K., et al. Managing atrial fibrillation in the very elderly patient: challenges and solutions. Vascular Health and Risk Management. 2015;11:555–562. doi: 10.2147/vhrm.s83664.
    1. Hindricks G., Potpara T., Dagres N., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) European Heart Journal. 2021;42(5):373–498. doi: 10.1093/eurheartj/ehaa612.
    1. Hu Z. C., Liu S. Y., Wu L. M., et al. Factors influencing adherence to non-vitamin K antagonist oral anticoagulants in the early period after atrial fibrillation catheter ablation in China. Chinese Medical Journal. 2020;133(16):1989–1991. doi: 10.1097/CM9.0000000000001000.
    1. Xiang X., Cao Y., Sun K., et al. Real world adherence to oral anticoagulant in non-valvular atrial fibrillation patients in China. Current Medical Research and Opinion. 2018;34(2):255–261. doi: 10.1080/03007995.2017.1391760.
    1. Liu T., Yang H. I., Gu L., et al. Current status and factors influencing Oral anticoagulant therapy among patients with non-valvular atrial fibrillation in Jiangsu province, China: a multi-center, cross-sectional study. BMC Cardiovascular Disorders. 2020;20(1):p. 22. doi: 10.1186/s12872-020-01330-6.
    1. Al-Shamiri M. Knowledge gaps about oral anticoagulant in Saudi patients. International Journal of Pharmaceutical Research & Allied Sciences. 2020;9:172–178.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere